Human embryonic kidney cells HEK-293 |
No difference in AT1 affinity to Ang A and Ang II ↑ affinity of AT2 for Ang A than for Ang II |
[17] |
Vascular smooth-muscle cells |
Dose-dependent ↑ in cytosolic calcium inhibited by AT1 antagonist EXP-3174 |
[17] |
proliferative effect Ang A > to Ang II |
[20] |
Abdominal aorta New Zealand White rabbits |
Vasoconstriction ↓ in vessels from animals fed with atherogenic diet |
[19] |
Isolated perfused kidney |
Dose-dependent vasoconstriction 90% of the maximal effect of Ang II inhibited by AT1 antagonist EXP-3174 no effect of AT2 antagonist PD123319 |
[17] |
Normotensive rats intrarenal administration |
↓ renal blood flow and ↑ renal vascular resistance ↓ effect of Ang A compared to Ang II improved by candesartan |
[18] |
Normotensive rats i.v. administration |
↑ BP ↓ by AT1-receptor blocker losartan no effect of AT2-antagonist PD123319 |
[20] |
Spontaneously hypertensive rats i.v. administration |
↑ BP both SHR and controls ↓ by AT1-receptor blocker candesartan no effect of AT2-antagonist PD123319 dose-dependent ↓ renal blood flow and ↑ renal vascular resistance in both SHR and controls ↓ effect of Ang A compared to Ang II no vasodilator response to Ang A or Ang II stimulation improved by candesartan no effect of AT2-antagonist PD123319 |
[18] |
AT1-knockout mice |
↑ BP in wild-type mice at ≈10× ↑ concentrations than Ang II no effect on BP in AT1A-knockout mice |
[17] |
↑ BP and cortical vascular resistance and ↓ cortical blood flow in wild-type mice by Ang A and Ang II abolished in AT1A-knockout mice |
[18] |
AT2-knockout mice |
↑ cortical vascular resistance and ↓ cortical blood flow inhibited by candesartan no effect of AT2-antagonist PD123319 |
[18] |